New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Certain tumor types do not remain at their point of origin but spread throughout the body and form metastases.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...